(3aS,4R,6R,7R,7aR)-7-Hydroxy-6-((2R,3R,4R)-3-hydroxy-2-triisopropylsilanyloxymethyl-3,4-dihydro-2H-pyran-4-yloxy)-4-triisopropylsilanyloxymethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2-one | 166021-02-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧吡喃
• 英文名称: (3aS,4R,6R,7R,7aR)-7-Hydroxy-6-((2R,3R,4R)-3-hydroxy-2-triisopropylsilanyloxymethyl-3,4-dihydro-2H-pyran-4-yloxy)-4-triisopropylsilanyloxymethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2-one
• 英文别名: (3aS,4R,6R,7R,7aR)-7-hydroxy-6-[[(2R,3R,4R)-3-hydroxy-2-[tri(propan-2-yl)silyloxymethyl]-3,4-dihydro-2H-pyran-4-yl]oxy]-4-[tri(propan-2-yl)silyloxymethyl]-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2-one
• CAS: 166021-02-9
• 化学式: C₃₁H₅₈O₁₀Si₂
• 分子量: 646.967
• InChiKey: VPEZEYMXEUNKDD-AQIHSDOCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.02
• 重原子数：
  43
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  122
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (3aS,4R,6R,7R,7aR)-7-Hydroxy-6-((2R,3R,4R)-3-hydroxy-2-triisopropylsilanyloxymethyl-3,4-dihydro-2H-pyran-4-yloxy)-4-triisopropylsilanyloxymethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2-one 在 咪唑 、 iodonium(di-γ-collidine) perchlorate 、 lithium hexamethyldisilazane 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 N-[(2S,3R,4R,5R,6R)-4-[[(3aS,4R,6R,7R,7aS)-7-[tert-butyl(dimethyl)silyl]oxy-2-oxo-4-[tri(propan-2-yl)silyloxymethyl]-4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-6-yl]oxy]-2-ethylsulfanyl-5-hydroxy-6-[tri(propan-2-yl)silyloxymethyl]oxan-3-yl]benzenesulfonamide
  参考文献：
  名称：

  Synthesis of Asialo GM₁. New Insights in the Application of Sulfonamidoglycosylation in Oligosaccharide Assembly:  Subtle Proximity Effects in the Stereochemical Governance of Glycosidation

  摘要：

  The total synthesis of asialo GM(1) (1a) has been accomplished, Using related chemistry, the methyl glycoside of the asialo compound (1b) has also been synthesized. These kinds of compounds have been identified as potential ligands for bacterial and viral infection sites, A simpler structure, which hits also been identified for its infection attracting structure in the context of glycopeptides and glycolipids (methyl glycoside 2), has also been synthesized. The key common phase in the syntheses involves the sulfonamidoglycosidation reaction which is used to create a beta-linkage leading to a galNAc residue joined to the C-4 hydroxyl group of a galactose unit either as a monosaccharide (see compound 2) or as C-4' in the contest of a lactosyl moiety, During the course of these studies there was encountered an unusual "proximal hydroxyl" directing effect. Thus, when C-4 on the galactose ring of an azaglycosylating donor bears a free hydroxyl (see, for instance, compound 13), beta-glycoside formation predominates. When this hydroxyl group is blocked, the process tends in the direction of alpha-glycoside formation (see compound 32), These findings were explained as arising from a critical intramolecular hydrogen bond between the C-4 axial hydroxyl of the galactose donor and its proximal pyranosidal ring oxygen. This interaction stabilizes conformations from which beta-glycosidation predominates.

  DOI：

  10.1021/ja9724957
• 作为产物：
  描述：

  2,6-脱水-5-脱氧-3,4-O-(氧代亚甲基)-1-O-(三异丙基硅烷基)-D-阿拉伯糖-己-5-烯糖 在 二甲基二环氧乙烷 、 zinc(II) chloride 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 0.33h， 生成 (3aS,4R,6R,7R,7aR)-7-Hydroxy-6-((2R,3R,4R)-3-hydroxy-2-triisopropylsilanyloxymethyl-3,4-dihydro-2H-pyran-4-yloxy)-4-triisopropylsilanyloxymethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyran-2-one
  参考文献：
  名称：

  人类乳腺肿瘤 (Globo-H) 抗原的全合成和结构证明

  摘要：

  Hakomori MBr1 抗原的全合成，在人类乳腺肿瘤上大量表达，是相关的。该构建涉及四种糖基的组装：（17（两次）、18、20 和 26）和 l-岩藻糖衍生物，34。作为状态函数的末端半乳糖环磺酰氨基半乳糖基化立体化学的敏感性在关键步骤中利用其C4醇的保护状态。（参见化合物 51 的形成。）该合成用于确认 Hakomori 结构的分配，并为免疫偶联铺平了道路。（见化合物 64。）

  DOI：

  10.1021/ja962048b

文献信息

• A Practical Total Synthesis of Globo-H for Use in Anticancer Vaccines
  作者：Insik Jeon、Karthik Iyer、Samuel J. Danishefsky

  DOI：10.1021/jo901682p

  日期：2009.11.6

  An improved synthesis of the hexasaccharide MBr1 antigen (globo-H) is reported. Enhanced efficiency in the synthesis was necessary for the scale-up production of globo-H, in order to advance globo-H-based anticancer vaccines to clinical trials. The key features of the improved synthesis include preactivation-based glycosylations and a revised iodosulfonimidation/rearrangement.

  据报道，六糖 MBr1 抗原 (globo-H) 的合成得到了改进。提高合成效率对于扩大 globo-H 的生产规模至关重要，以便将基于 globo-H 的抗癌疫苗推进临床试验。改进合成的关键特征包括基于预激活的糖基化和改进的碘磺酰亚胺化/重排。
• Total Synthesis of a Human Breast Tumor Associated Antigen
  作者：Mark T. Bilodeau、Tae Kyo Park、Shuanghua Hu、John T. Randolph、Samuel J. Danishefsky、Philip O. Livingston、Shengli Zhang

  DOI：10.1021/ja00134a043

  日期：1995.7
• A total synthesis of a stage specific pentasaccharide embryogenesis marker
  作者：Tae Kyo Park、In Jong Kim、Samuel J. Danishefsky

  DOI：10.1016/0040-4039(95)01962-h

  日期：1995.12

  A thioglycoside coupling mediated by methyl triflate was used to generate Stage Specific Embryonic Antigen-3.
• Synthetic and Immunological Studies on Clustered Modes of Mucin-Related Tn and TF O-Linked Antigens:  The Preparation of a Glycopeptide-Based Vaccine for Clinical Trials against Prostate Cancer
  作者：Scott D. Kuduk、Jacob B. Schwarz、Xiao-Tao Chen、Peter W. Glunz、Dalibor Sames、Govindaswami Ragupathi、Philip O. Livingston、Samuel J. Danishefsky

  DOI：10.1021/ja9825128

  日期：1998.12.1

  The syntheses of two tumor-associated carbohydrate antigens, Tn and TF, have been achieved using glycal assembly and cassette methodologies. These synthetic antigens were subsequently clustered (c) and immunoconjugated to a carrier protein (KLH or BSA) or a synthetic lipopeptide (pam) for immunological study. Three Tn conjugates were used to vaccinate groups of mice, and all preparations proved to be immunogenic. The Tn(c) covalently linked to KLH (27-KLH) plus the adjuvant QS-21 was the optimal vaccine, inducing high median IgM and IgG titers against Tn(c) by ELISA. These antibodies were strongly reactive with the Tn(c) positive human colon cancer cell line LS-C but not the Tn(c) negative colon cancer cell Line LS-B by FAGS. The antibodies' reactivities with natural antigens were inhibited with synthetic Tn(c) but not with structurally unrelated compounds. On the basis of these results, vaccines containing 27-KLH and 30-pam plus QS-21 are being tested in patients with prostate cancer.